Shares of OraSure Technologies Inc. (NASDAQ:OSUR) rose 5.4% during trading on Wednesday . The company traded as high as $6.29 and last traded at $6.29, with a volume of 628,946 shares traded. The stock had previously closed at $5.97.

OSUR has been the subject of a number of research reports. TheStreet upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, April 14th. Canaccord Genuity reiterated a “buy” rating and issued a $9.00 price objective on shares of OraSure Technologies in a research report on Friday, March 18th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $8.00 price objective for the company in a research report on Saturday, April 16th. BTIG Research reiterated a “buy” rating and issued a $9.00 price objective on shares of OraSure Technologies in a research report on Wednesday, June 29th. Finally, Mizuho reiterated a “buy” rating and issued a $8.00 price objective on shares of OraSure Technologies in a research report on Friday, May 6th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $8.08.

The company has a market cap of $345.66 million and a PE ratio of 35.00. The stock has a 50-day moving average price of $7.06 and a 200 day moving average price of $6.72.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.02. The business had revenue of $29.10 million for the quarter, compared to the consensus estimate of $28.82 million. The business’s quarterly revenue was up 7.4% on a year-over-year basis. On average, equities analysts expect that OraSure Technologies Inc. will post $0.25 EPS for the current year.

Other hedge funds have made changes to their positions in the company. Casdin Capital LLC acquired a new stake in shares of OraSure Technologies during the fourth quarter valued at $1,095,000. Oxford Asset Management acquired a new stake in shares of OraSure Technologies during the fourth quarter valued at $1,209,000. American Century Companies Inc. acquired a new stake in shares of OraSure Technologies during the fourth quarter valued at $1,371,000. Finally, Morgan Stanley increased its stake in shares of OraSure Technologies by 40.9% in the fourth quarter. Morgan Stanley now owns 363,707 shares of the company’s stock valued at $2,342,000 after buying an additional 105,627 shares in the last quarter.

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test, OraQuick ADVANCE, OraSure HIV-1 oral specimen collection device, OraQuick HCV rapid antibody test, Intercept oral fluid drug testing system, OraSure QuickFlu Rapid Flu A&B Test and Q.E.D.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.